• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Clinical Development Programs for Opioid Conversion; Public Workshop; Request for Comments

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) is announcing a scientific workshop to address public health concerns associated with the inclusion of equianalgesic opioid  conversion tables in opioid product labels.  Discussion will focus on the available data supporting the use of equianalgesic opioid conversion tables, problems associated with their use, strategies used in clinical practice to convert patients from one opioid analgesic product to another, gaps in existing knowledge regarding equianalgesic opioid conversion in clinical practice, a research agenda to address these gaps, and identification of mechanisms for communicating opioid analgesic conversion strategies to prescribers.

Date:            July 29, 2013

Time:            8:00 a.m. to 4:30 p.m.

Location:     FDA White Oak Campus
                      10903 New Hampshire Avenue,
                      Bldg. 31, Room 1503 (Great Room)
                      Silver Spring, Maryland 20993

Registration to Attend the Workshop and Requests to Participate in Open Public Hearing: If you wish to attend the meeting or provide testimony  for the open public hearing , please email your registration to: IssuesWithOpioids@fda.hhs.gov by July 15, 2013.  Those without email access may register by contacting one of the persons listed in the Contacts section of the document. Please provide complete contact information for each attendee, including name, title, affiliation, address, email address, and telephone number. 

Webcast